嵌合抗原受体
CD19
细胞疗法
抗原
T细胞
医学
癌症研究
免疫学
细胞因子释放综合征
细胞
T细胞受体
生物
免疫疗法
免疫系统
遗传学
作者
Zhaokai Zhou,Ge Zhang,Yudi Xu,Shuai Yang,Jiaojiao Wang,Zhengrui Li,Fu Peng,Qiong Lu
出处
期刊:Cancer Letters
[Elsevier]
日期:2024-06-24
卷期号:597: 217083-217083
被引量:2
标识
DOI:10.1016/j.canlet.2024.217083
摘要
The U.S. Food and Drug Administration (FDA) has reported cases of T-cell malignancies, including CAR-positive lymphomas, in patients receiving B cell maturation antigen (BCMA)- or CD19-targeted autologous CAR-T cell immunotherapy. These reports were derived from clinical trials and/or post-marketing adverse event data. This finding has attracted widespread attention. Therefore, it is essential to explore the potential mechanisms by which chimeric antigen receptor (CAR)-T cell therapy triggers secondary T-cell cancers to further guarantee the safety of CAR-T cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI